Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

First Commercial mRNA Vaccine Approval Expected By 2029 Says Kuick Research First Commercial mRNA Vaccine Approval Expected By 2029 Says Kuick Research

mRNA Cancer Vaccines Clinical Trials Ongoing Research Development Insight

Advanced Micro Devices

Exxon Mobil

The minutes from the December Fed meeting signaled central bankers' uncertainty over potential Trump administration policies.

Stock Market Today: Stocks End Mixed After FOMC Minutes

Moderna stock has been volatile this week as the first death in the U.S. connected to bird flu was reported. Here's what you need to know.

Moderna Stock Is Volatile Amid Bird Flu Developments

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

Moderna Shares Spike on H5N1 News—What's Next for Investors?

Merck

Pfizer

UBS lowered its price targets for Pfizer, Merck, and Moderna stocks.

There's a ‘Shadow' Over Biotech Stocks. Why It Isn‘t All Bad News.

The stock price of Moderna saw a 12% jump on Tuesday, January 7, amid rising cases of Covid-19 and flu in the U.S. Along with Moderna, stocks of other vaccine makers also saw an uptick. Novavax was up 11%, while BioNTech ADR was up 5%.

Why Did Moderna Stock Rise 12%?

Introduction of a Universal Coronavirus Vaccine : A robust cross-immunity effect to combat virus mutations. SEOUL, South Korea , Jan. 8, 2025 /PRNewswire/ -- The COVID-19 pandemic has fundamentally transformed global healthcare systems and vaccine technologies.

Dx&Vx, From mRNA Vaccines to Nanoparticle Vaccines era of Next-Generation Vaccines

Novavax

After undergoing years of stock market decline as reporting and awareness about the COVID-19 pandemic subsided, major vaccine stocks received a major, if grim, boost in early 2025.

Here's why vaccine stocks are surging in 2025

The first bird-flu fatality in the United States sparks investor interest in several vaccine makers that are developing experimental H5N1 vaccines.

Vaccine Stocks Jump After CDC Reports First US Bird-Flu Death

Moderna (MRNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Moderna (MRNA) Stock Jumps 11.7%: Will It Continue to Soar?

D.R. Horton

It might seem that valuation is no longer important for investors. Stocks that have sky-high valuation metrics continue to soar.

Prediction: These Could Be the Best-Performing Value Stocks Through 2030

Moderna (MRNA) shares soared Tuesday as investors placed bets that the pharmaceutical giant's development of an H5N1 bird flu vaccine could boost sales after the first death linked to the disease was reported in the U.S this week.

Moderna Price Levels to Watch After Stock's 12% Surge on Tuesday

Without our health… time to look at Moderna's stock (NASDAQ: MRNA).

Is The Moderna Stock (MRNA) Rally For Real?

Major U.S. equities indexes lost ground as the latest Purchasing Managers' Index (PMI) showed an expansion in the manufacturing sector but revealed an increase in the "prices paid" index during December.

S&P 500 Gains and Losses Today: Moderna Soars on Bird Flu Vaccine Potential

Moderna (MRNA) shares jumped more than 10% to lead S&P 500 gainers Tuesday, a day after the first bird-flu death was reported in the U.S. The biotech company is developing a vaccine for H5N1.

Moderna Stock Soars After First US Bird-Flu Death

Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares surged alongside rival vaccine makers on Tuesday after news broke of the first human death related to the H5 bird flu strain in the US. America's Centers for Disease Control and Prevention (CDC) on Monday reported an elderly patient in Louisiana with underlying medical conditions had died from the disease.

Moderna among vaccine makers to surge on US bird flu death

BioNTech SE

Moderna stock surged Tuesday after the Centers for Disease Control and Prevention noted a two-week spike in positive Covid tests. The post Moderna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid Spike appeared first on Investor's Business Daily.

Moderna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid Spike

The company is one of a few drugmakers currently developing a vaccine for the illness, which is spreading rapidly through North America.

Moderna Stock Jumps Amid Bird Flu Vaccine Hope After First U.S. Death

NVIDIA

Apple

Arista Networks

Booking Hlds

Enphase Energy

Mastercard

Texas Pacific Land Trust

Vertex, Inc.

A company's return on average assets sheds light on how well its management team has allocated investors' money.

10 stocks making best use of investors' money. Here's who beats Nvidia.

In the latest trading session, Moderna (MRNA) closed at $42.18, marking a +0.43% move from the previous day.

Moderna (MRNA) Rises But Trails Market: What Investors Should Know

Moderna's partnership with Merck in personalized cancer therapies and promising Phase III trials support a speculative 'Buy' for long-term investors with high-risk tolerance. Despite a tough 2024, MRNA's pipeline reprioritization and $9 billion cash reserve position it for potential blockbuster products and revenue growth by 2028. Financial discipline has reduced cash burn and extended runway, with upcoming Phase III results in oncology and CMV expected to drive future profitability.

Moderna: From Breakthrough COVID-19 Vaccines To Personalized Cancer Therapies

Intel

Walgreens

Of the 503 stocks in the S&P 500 (some companies have two classes of stocks that are included) fewer than 30% of them, or 148 stocks, beat the index's average return of 23.31% in 2024.

Can The 3 Worst S&P 500 Stocks in 2024 Bounce Back in 2025?

Moderna ends 2024 as one of the worst-performing Nasdaq-100 stocks, but it presents a contrarian play for 2025 due to vaccine catalysts. The stock is down to $40 with a $15 billion market cap, despite having $3+ billion in revenue and a promising pipeline. Moderna's spending issue is a concern, but the potential of its CMV and cancer vaccines could significantly boost sales and justify current R&D expenses.

Moderna: 2025 Contrarian Play

Shares have been hammered by disappointing Covid vaccine sales, the company's heavy losses—an estimated $9 a share for 2024—and management's move to push out the year of projected profitability to 2028 from 2026.

This Biotech Is One of the S&P 500's Worst Performers. It Looks Too Cheap.

Biogen

Celanese

Dollar General

Dollar Tree

Estee Lauder

Humana

Also: Technical analysis for trading in shares of Nvidia, how MicroStrategy burns cash, and tips for people with student loans in 2025

News for Moderna Stock (MRNA)